YOLFTbeta
Vor Biopharma Inc

Vor Biopharma Inc

VOR · NASDAQ · Healthcare / Biotechnology

19.42USD+0.10 (+0.52%)

Price History

Full chart

Market Stats

Previous Close19.32
Open19.32
Day Range18.16 – 19.49
52-Week Range6.50 – 49.64
Volume738.72K
Market Cap1.10B
P/E (TTM)0.10
Forward P/E0.00
EPS180.58
Dividend Yield0.00%
Beta1.72
50-Day Avg21.98
200-Day Avg16.55

About

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jean-Paul Kress M.D.
  • Employees76
  • Headquarters500 Boylston Street, Boston, MA, United States, 02116, USA
  • Websitehttps://www.vorbio.com

Leadership

  • Dr. Jean-Paul Kress M.D.Chairman, President & CEO · b. 1965
  • Mr. Sandesh Mahatme L.L.M.Chief Business Officer & CFO · b. 1965
  • Dr. Robert Ang M.B.A., M.D., MBBSStrategic Advisor · b. 1975
  • Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.Scientific Founder & Chairman of Scientific Advisory Board · b. 1971
  • Ms. Adi OsovskyGeneral Counsel
  • Ms. Carol Lincoln CCPHead of Human Resources
  • Mr. Dallan MurrayChief Commercial Officer · b. 1970
  • Dr. Navid Z. Khan Ph.D.Chief Medical Affairs Officer
  • Dr. Jeremy Sokolove M.D.Chief Medical Officer · b. 1974

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000
Cost of Revenue20.00K91.00K1.39M4.45M8.96M3.49M3.53M-
Gross Profit-20.00K-91.00K-1.39M-4.45M-8.96M-3.49M-3.53M-
Operating Expense2.84M10.33M41.98M64.57M84.46M122.54M117.66M-
Operating Income-2.86M-10.42M-43.37M-69.02M-93.42M-126.04M-121.19M-371.64M
EBITDA-2.84M-10.14M-42.76M-67.47M-83.13M-114.37M-113.39M-693.09M
Net Income-4.15M-10.84M-43.34M-68.90M-92.09M-117.86M-116.91M-695.98M
R&D2.43M6.20M31.62M47.53M64.55M94.31M93.31M321.53M
Interest Expense1.00M608.00K01.55M1.32M---

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.01M9.83M75.91M242.59M299.37M209.83M142.89M464.13M
Total Liabilities7.77M2.19M27.64M26.33M48.76M59.10M46.23M628.44M
Total Equity-6.77M7.64M48.27M216.26M250.61M150.72M96.66M-164.31M
Cash929.00K6.47M48.54M119.80M57.71M31.36M81.95M396.49M
Total Debt4.46M-18.29M18.01M38.91M35.66M31.83M3.00M
Net Debt3.53M-6.47M-30.25M-101.79M-18.79M4.30M-50.12M-393.49M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.66M-9.86M-36.29M-69.14M-85.14M-100.29M-99.66M-142.71M
Investing Cash Flow-748.00K-748.00K-4.16M-91.65M-94.09M71.01M96.86M-48.80M
Financing Cash Flow2.46M17.70M82.53M232.91M117.14M2.94M53.39M503.81M
Capital Expenditure748.00K748.00K4.16M3.89M8.46M1.07M229.00K941.00K
Free Cash Flow-2.66M-10.60M-40.45M-73.04M-93.61M-101.36M-99.89M-143.65M
FCF to OCF100.00%107.59%111.47%105.63%109.94%101.07%100.23%100.66%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 18, 2020Mar 25, 2021May 6, 2021Aug 9, 2021Nov 10, 2021Mar 14, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 10, 2023Nov 7, 2023Mar 20, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 18, 2025May 14, 2025Aug 12, 2025Nov 13, 2025Mar 30, 2026May 13, 2026Aug 11, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.000.00-5.33-4.40-15.20-9.27-11.50-0.57-10.29-13.00-11.89-0.60-7.77-8.46-9.17-0.50-7.63-8.29-0.40-0.31-4.16-11.80-4.10-1.19-0.78-0.69-0.81
EPS Actual-1.33-1.33-2.62-4.14-4.14-4.67-7.26-217.49-13.40-10.00-10.00-0.48-12.20-11.60-12.60-0.52-8.60-9.00-9.80-0.39-9.00-8.20-8.00-0.44-5.20-251.20-121.63307.53-0.73-0.80-
Surprise-------36.21%-4842.95%11.84%-7.87%13.04%15.79%-18.56%10.77%-5.97%13.33%-10.68%-6.38%-6.87%22.00%-17.96%1.09%-1900.00%-43.46%-25.00%-2028.81%-2866.59%25921.16%6.41%-15.94%-
Timing------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap1.10B
Enterprise Value682.72M
Trailing P/E0.10
Forward P/E0.00
Price / Sales0.00
Price / Book0.66
EPS180.58
Book Value-3.68
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-117.28M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-125.43%
Return on Assets-21.37%
Shares Outstanding59.16M
Shares Float37.23M
Beta1.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 5 analystsTarget 39.00
  • Hold
    5

Ownership Breakdown

Institutions
86.80%
Insiders
9.27%
Retail / Other
3.93%

Top Institutional Holders

  • TCG Crossover Management, LLC
    5.67M9.59%
  • RA Capital Management, LLC
    5.40M9.14%
  • FCPM III SERVICES BV
    4.12M6.96%
  • VR Adviser, LLC
    3.04M5.14%
  • Frazier Life Sciences Management, L.P.
    2.54M4.30%
  • Caligan Partners LP
    1.93M3.25%
  • Paradigm Biocapital Advisors LP
    1.75M2.96%
  • Great Point Partners LLC
    1.70M2.87%
  • FMR Inc
    1.54M2.60%
  • Vanguard Capital Management, LLC
    1.43M2.42%
  • Marshall Wace Asset Management Ltd
    1.15M1.95%
  • State Street Corp
    1.12M1.89%
  • NEXTBio Capital Management LP
    889.16K1.50%
  • BlackRock Inc
    794.76K1.34%
  • Rosalind Advisors, Inc.
    700.00K1.18%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    1.85M3.13%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.55M2.62%
  • Fidelity Select Biotechnology
    1.40M2.37%
  • Fidelity Small Cap Growth
    1.27M2.15%
  • iShares Russell 2000 ETF
    1.04M1.76%

Stock Splits

  • Sep 19, 20251:20